Resona Asset Management Co. Ltd. Sells 16,324 Shares of Johnson & Johnson $JNJ

Resona Asset Management Co. Ltd. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.1% during the third quarter, HoldingsChannel reports. The institutional investor owned 771,802 shares of the company’s stock after selling 16,324 shares during the period. Johnson & Johnson accounts for 1.0% of Resona Asset Management Co. Ltd.’s portfolio, making the stock its 17th largest position. Resona Asset Management Co. Ltd.’s holdings in Johnson & Johnson were worth $204,801,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. National Pension Service increased its position in Johnson & Johnson by 1.3% during the second quarter. National Pension Service now owns 5,226,968 shares of the company’s stock worth $1,327,493,000 after purchasing an additional 67,484 shares during the last quarter. IFP Advisors Inc boosted its holdings in Johnson & Johnson by 8.8% in the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock valued at $9,844,000 after purchasing an additional 3,133 shares during the last quarter. Elefante Mark B boosted its holdings in Johnson & Johnson by 9.8% in the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company’s stock valued at $7,285,000 after purchasing an additional 2,563 shares during the last quarter. AMG Asset Management Group Inc. boosted its holdings in Johnson & Johnson by 172.0% in the 3rd quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company’s stock valued at $1,020,000 after purchasing an additional 2,436 shares during the last quarter. Finally, Gradient Investments LLC grew its stake in shares of Johnson & Johnson by 9.9% in the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock valued at $38,815,000 after buying an additional 13,737 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on JNJ. Johnson Rice lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Royal Bank Of Canada decreased their price objective on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a report on Wednesday, October 14th. Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Bank of America reissued a “neutral” rating and set a $278.00 target price on shares of Johnson & Johnson in a research note on Tuesday, September 29th. Finally, Evercore set a $300.00 target price on Johnson & Johnson in a research report on Tuesday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $276.54.

Get Our Latest Stock Analysis on Johnson & Johnson

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Elizabeth Forminard sold 13,072 shares of the company’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. The trade was a 43.48% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by company insiders.

Latest Johnson & Johnson News

Investors following JNJ have been watching these news items:

  • Positive Sentiment: J&J announced the first U.S. commercial installation of its OTTAVA surgical robot at a Houston hospital, an early step in bringing the platform to market and expanding its surgical-technology business. Article
  • Positive Sentiment: The company submitted an FDA application to expand CAPLYTA’s use to bipolar I mania or mixed episodes, supported by two positive Phase 3 studies. Approval is not guaranteed, but another indication could broaden the drug’s growth potential. Article
  • Neutral Sentiment: JPMorgan raised its JNJ price target to $300 from $285 but kept a “neutral” rating, signaling a higher valuation estimate without a change in its overall recommendation. Analyst rating

Johnson & Johnson Trading Up 1.3%

Shares of JNJ stock opened at $270.54 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The firm has a market cap of $651.27 billion, a PE ratio of 40.99, a price-to-earnings-growth ratio of 2.79 and a beta of 0.22. The company has a 50-day moving average of $267.53 and a two-hundred day moving average of $250.98. Johnson & Johnson has a 1-year low of $199.90 and a 1-year high of $290.25.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period last year, the business earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts predict that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.